Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 318

1.

Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study.

Bond J, Graux C, Lhermitte L, Lara D, Cluzeau T, Leguay T, Cieslak A, Trinquand A, Pastoret C, Belhocine M, Spicuglia S, Lheritier V, Leprêtre S, Thomas X, Huguet F, Ifrah N, Dombret H, Macintyre E, Boissel N, Asnafi V.

J Clin Oncol. 2017 Jun 12:JCO2016718585. doi: 10.1200/JCO.2016.71.8585. [Epub ahead of print]

PMID:
28605290
2.

TCRα rearrangments identify a subgroup of NKL-deregulated adult T-ALLs associated with favorable outcome.

Villarese P, Lours C, Trinquand A, Le Noir S, Belhocine M, Lhermitte L, Cieslak A, Tesio M, Petit A, LeLorch M, Spicuglia S, Ifrah N, Dombret H, Langerak AW, Boissel N, Macintyre E, Asnafi V.

Leukemia. 2017 Jun 8. doi: 10.1038/leu.2017.176. [Epub ahead of print]

PMID:
28592888
3.

Age-related clinical and biological features of PTEN abnormalities in T-cell acute lymphoblastic leukaemia.

Tesio M, Trinquand A, Ballerini P, Hypolite G, Lhermitte L, Petit A, Ifrah N, Baruchel A, Dombret H, Macintyre E, Asnafi V.

Leukemia. 2017 May 25. doi: 10.1038/leu.2017.157. [Epub ahead of print]

PMID:
28539671
4.

BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.

Vidal V, Robert G, Goursaud L, Durand L, Ginet C, Karsenti JM, Luciano F, Gastaud L, Garnier G, Braun T, Hirsch P, Raffoux E, Nloga AM, Padua RA, Dombret H, Rohrlich P, Ades L, Chomienne C, Auberger P, Fenaux P, Cluzeau T.

Oncotarget. 2017 Apr 27. doi: 10.18632/oncotarget.17482. [Epub ahead of print]

5.

Hypomethylating Agents as a Therapy for AML.

Gardin C, Dombret H.

Curr Hematol Malig Rep. 2017 Feb;12(1):1-10. doi: 10.1007/s11899-017-0363-4. Review.

PMID:
28286907
6.

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.

Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS.

N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783.

PMID:
28249141
7.

Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission.

Thomas X, de Botton S, Chevret S, Caillot D, Raffoux E, Lemasle E, Marolleau JP, Berthon C, Pigneux A, Vey N, Reman O, Simon M, Recher C, Cahn JY, Hermine O, Castaigne S, Celli-Lebras K, Ifrah N, Preudhomme C, Terré C, Dombret H.

J Clin Oncol. 2017 Apr 10;35(11):1223-1230. doi: 10.1200/JCO.2016.70.4551. Epub 2017 Feb 21.

PMID:
28221862
8.

Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.

Pleyer L, Döhner H, Dombret H, Seymour JF, Schuh AC, Beach CL, Swern AS, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, Thaler J, Halter B, Machherndl Spandl S, Zebisch A, Pichler A, Pfeilstöcker M, Autzinger EM, Lang A, Geissler K, Voskova D, Sperr WR, Hojas S, Rogulj IM, Andel J, Greil R.

Int J Mol Sci. 2017 Feb 15;18(2). pii: E415. doi: 10.3390/ijms18020415.

9.

Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.

Chevallier P, Chantepie S, Huguet F, Raffoux E, Thomas X, Leguay T, Marchand T, Isnard F, Charbonnier A, Maury S, Gallego-Hernanz MP, Robillard N, Guillaume T, Peterlin P, Garnier A, Rialland F, Le Houerou C, Goldenberg DM, Wegener WA, Béné MC, Dombret H.

Haematologica. 2017 May;102(5):e184-e186. doi: 10.3324/haematol.2016.159905. Epub 2017 Feb 2. No abstract available.

10.

Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA.

Wang L, Raffoux E, Thomas X, Yakoub-Agha I, Bouhris JH, de Botton S, Michallet M, Quoc SN, Chantepie S, Deconinck E, Caillot D, Turlure P, Vigouroux S, Pigneux A, Huynh A, Malfuson JV, Loschi M, Socie G, Dombret H, de la Tour RP, Cluzeau T.

Leuk Res. 2017 Mar;54:12-16. doi: 10.1016/j.leukres.2017.01.002. Epub 2017 Jan 5.

PMID:
28088653
11.

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.

Balsat M, Renneville A, Thomas X, de Botton S, Caillot D, Marceau A, Lemasle E, Marolleau JP, Nibourel O, Berthon C, Raffoux E, Pigneux A, Rodriguez C, Vey N, Cayuela JM, Hayette S, Braun T, Coudé MM, Terre C, Celli-Lebras K, Dombret H, Preudhomme C, Boissel N.

J Clin Oncol. 2017 Jan 10;35(2):185-193. Epub 2016 Nov 14.

PMID:
28056203
12.

Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies.

Ades L, Prebet T, Stamatoullas A, Recher C, Guieze R, Raffoux E, Bouabdallah K, Hunault M, Wattel E, Stalnikiewicz L, Toma A, Dombret H, Vey N, Sebert M, Gardin C, Chaffaut C, Chevret S, Fenaux P.

Haematologica. 2017 Apr;102(4):728-735. doi: 10.3324/haematol.2016.151894. Epub 2016 Dec 29.

13.

Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study.

Desjonquères A, Chevallier P, Thomas X, Huguet F, Leguay T, Bernard M, Bay JO, Tavernier E, Charbonnier A, Isnard F, Hunault M, Turlure P, Renaud M, Bastié JN, Himberlin C, Lepretre S, Lioure B, Lhéritier V, Asnafi V, Beldjord K, Lafage-Pochitaloff M, Béné MC, Ifrah N, Dombret H.

Blood Cancer J. 2016 Dec 9;6(12):e504. doi: 10.1038/bcj.2016.111.

14.

A 17-gene stemness score for rapid determination of risk in acute leukaemia.

Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, Arruda A, Popescu A, Gupta V, Schimmer AD, Schuh AC, Yee KW, Bullinger L, Herold T, Görlich D, Büchner T, Hiddemann W, Berdel WE, Wörmann B, Cheok M, Preudhomme C, Dombret H, Metzeler K, Buske C, Löwenberg B, Valk PJ, Zandstra PW, Minden MD, Dick JE, Wang JC.

Nature. 2016 Dec 15;540(7633):433-437. doi: 10.1038/nature20598. Epub 2016 Dec 7.

PMID:
27926740
15.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD.

Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28. Review.

16.

Copy-number analysis identified new prognostic marker in acute myeloid leukemia.

Nibourel O, Guihard S, Roumier C, Pottier N, Terre C, Paquet A, Peyrouze P, Geffroy S, Quentin S, Alberdi A, Abdelali RB, Renneville A, Demay C, Celli-Lebras K, Barbry P, Quesnel B, Castaigne S, Dombret H, Soulier J, Preudhomme C, Cheok MH.

Leukemia. 2017 Mar;31(3):555-564. doi: 10.1038/leu.2016.265. Epub 2016 Sep 30.

PMID:
27686867
17.

Healthcare burden and reimbursement of hospitalization during chemotherapy for adults with Ph-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in France: a retrospective chart review.

Dombret H, Thomas X, Chevallier P, Nivot E, Reitan J, Barber B, Barlev A, Mohty M.

J Med Econ. 2016 Nov;19(11):1034-1039. Epub 2016 Jun 3.

PMID:
27207188
18.

Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia.

Seymour JF, Döhner H, Minden MD, Stone R, Gambini D, Dougherty D, Beach CL, Weaver J, Dombret H.

Leuk Lymphoma. 2017 Jun;58(6):1412-1423. doi: 10.1080/10428194.2016.1243680. Epub 2016 Oct 14.

PMID:
27739920
19.

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia.

Gökbuget N, Kelsh M, Chia V, Advani A, Bassan R, Dombret H, Doubek M, Fielding AK, Giebel S, Haddad V, Hoelzer D, Holland C, Ifrah N, Katz A, Maniar T, Martinelli G, Morgades M, O'Brien S, Ribera JM, Rowe JM, Stein A, Topp M, Wadleigh M, Kantarjian H.

Blood Cancer J. 2016 Sep 23;6(9):e473. doi: 10.1038/bcj.2016.84.

20.

Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.

Maury S, Chevret S, Thomas X, Heim D, Leguay T, Huguet F, Chevallier P, Hunault M, Boissel N, Escoffre-Barbe M, Hess U, Vey N, Pignon JM, Braun T, Marolleau JP, Cahn JY, Chalandon Y, Lhéritier V, Beldjord K, Béné MC, Ifrah N, Dombret H; for GRAALL.

N Engl J Med. 2016 Sep 15;375(11):1044-53. doi: 10.1056/NEJMoa1605085.

Supplemental Content

Loading ...
Support Center